# Exosomal Non-Coding RNAs in Pancreatic Cancer: From Mechanisms to Clinical Applications

## TL;DR

This paper reviews how exosomal non-coding RNAs contribute to pancreatic cancer and their potential as biomarkers for diagnosis and treatment.

## Contribution

The paper systematically summarizes the roles and potential clinical applications of exosomal non-coding RNAs in pancreatic cancer.

## Key findings

- Exosomal non-coding RNAs influence tumor progression and immune evasion in pancreatic cancer.
- These ncRNAs show promise as biomarkers for early diagnosis and prognosis.
- They also play roles in chemoresistance and tumor microenvironment remodeling.

## Abstract

Pancreatic cancer (PC) is an extremely aggressive cancer of the digestive system with insidious onset and the lack of effective biomarkers, resulting in late-stage diagnosis and poor prognosis. Exosomal non-coding RNAs (ncRNAs) are key mediators of intercellular communication that drive PC initiation and advancement. By modulating gene expression, they impact tumor microenvironment (TME) remodeling, proliferation, migration, apoptosis, and immune evasion. Critically, exosomal ncRNAs serve as promising biomarkers for early diagnosis and prognostic assessment. This review summarizes the current research achievements regarding exosomal ncRNAs in PC, systematically elaborating on their roles in tumor occurrence, metastasis, chemoresistance and the TME. Furthermore, by integrating the potential of exosomal ncRNAs in the diagnosis, treatment and prognosis of PC and by highlighting the challenges and future directions, this review aims to offer novel insights for future research and clinical translation of exosomal ncRNAs in PC.